Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses.

BACKGROUND This study aimed to evaluate the safety and effectiveness of the BNT162b2 vaccine in immunocompromised adolescents and young adults. RESEARCH DESIGN AND METHODS The study conducted a meta-analysis of post-marketing studies examining BNT162b2 vaccination efficacy and safety among immunocompromised adolescents and young adults worldwide. The review included nine studies and 513 individuals aged between 12 and 24.3 years. The study used a random effect model to estimate pooled proportions, log relative risk, and mean difference, and assessed heterogeneity using the I2 test. The study also examined publication bias using Egger's regression and Begg's rank correlation and assessed bias risk using ROBINS-I. RESULTS The pooled proportions of combined local and systemic reactions after the first and second doses were 30% and 32%, respectively. Adverse events following immunization (AEFI) were most frequent in rheumatic diseases (40%) and least frequent in cystic fibrosis (27%), although hospitalizations for AEFIs were rare. The pooled estimations did not show a statistically significant difference between immunocompromised individuals and healthy controls for neutralizing antibodies, measured IgG, or vaccine effectiveness after the primary dose. However, the evidence quality is low to moderate due to a high risk of bias, and no study could rule out the risk of selection bias, ascertainment bias, or selective outcome reporting. CONCLUSIONS This study provides preliminary evidence that the BNT162b2 vaccine is safe and effective in immunocompromised adolescents and young adults, but with low to moderate evidence quality due to bias risk. The study calls for improved methodological quality in studies involving specific populations.

[1]  S. Sivasampu,et al.  Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study , 2022, Vaccine.

[2]  T. Puthanakit,et al.  Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases , 2022, Vaccines.

[3]  Vasiliki Efthymiou,et al.  Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis , 2022, Journal of Cystic Fibrosis.

[4]  William F. Fadel,et al.  Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[5]  G. Shefer,et al.  Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications , 2022, Rheumatology.

[6]  B. Piccini,et al.  COVID‐19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects , 2022, Pediatric diabetes.

[7]  P. Palma,et al.  Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome , 2022, Journal of clinical medicine.

[8]  P. Dormitzer,et al.  A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults , 2021, Nature Communications.

[9]  E. Ingulli,et al.  Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients , 2021, Pediatric Nephrology.

[10]  S. Hober,et al.  Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial , 2021, EBioMedicine.

[11]  M. Tsolia,et al.  Safety and tolerability of the COVID‐19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors , 2021, Arthritis & rheumatology.

[12]  K. Syrigos,et al.  Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection , 2021, Vaccines.

[13]  A. Finn,et al.  Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years , 2021, Archives of disease in childhood.

[14]  J. Gargano,et al.  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[15]  S. Gupta,et al.  Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase , 2021, Pediatric blood & cancer.

[16]  X. de Lamballerie,et al.  The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience , 2021, European Journal of Cancer.

[17]  A. Huppert,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.

[18]  Manish M Patel,et al.  Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020. , 2020, The Journal of infectious diseases.

[19]  R. Schmidt-Ott,et al.  Vaccination of special populations: Protecting the vulnerable. , 2016, Vaccine.

[20]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[21]  Tiejun Tong,et al.  Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range , 2015, Statistical methods in medical research.

[22]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[23]  OUP accepted manuscript , 2022, Rheumatology.